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Sdepends on the differential diagnoses and the EBUS-
FNA team’s experience. We recommend initial verifica-
tion of every benign or nondiagnostic cytology finding
with a surgical biopsy, and then the EBUS-FNA team
will have accurately determined the diagnostic perfor-
mance of EBUS-FNA for benign disease on its own.CONCLUSIONS
We conclude that it is imperative for thoracic surgeons to
become facile with EBUS-FNA for several reasons: (1) to
accurately use EBUS-FNA as a diagnostic tool in patients
with thoracic diseases, (2) to perform EBUS-FNA following
appropriate oncologic principles (ie, proper sampling of
standard MLN stations); and (3) to streamline patient care,
because thoracic surgeons have the ability to perform addi-
tional interventions at the same time as EBUS-FNA.References
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Dr Hiran Fernando (Boston, Mass). Dr Andrade, a common
clinical challenge for thoracic surgeons is accurately diagnosing
a patient with a specific benign pathology, such as sarcoidosis,
and often these patients will have a number of diagnostic proce-
dures before referral to a thoracic surgeon, including transbron-
chial needle aspiration or fine-needle aspiration. You describe
success rates for benign and malignant diagnoses, and you separate
these in Table 3 in your article. You mention that you have a lower
sensitivity for a benign diagnosis of 72.7% versus 87.9% for ma-
lignancy. Do you mean that this 72.7% was simply to make a be-
nign rather than a cancer diagnosis or does this sensitivity refer to
actually making a specific benign diagnosis, such as sarcoid or his-
toplasmosis? If you suspect that a patient up front has a benign di-
agnosis in a lymph node station that would be accessible by
mediastinoscopy where you would get the whole lymph node,
would you recommend mediastinoscopy for that patient or an ini-
tial EBUS on the basis of your results, and what would be your rea-
soning for your approach?
Dr Andrade. In terms of the first question, the way we broke the
benign analysis down was by presumptive diagnosis. That’s what
the calculation reflects. Can you repeat your second question
once again, please?
Dr Fernando. If you have a specific benign cause, for instance,
if a pulmonologist sends you a patient with a possible diagnosis of
sarcoidosis, would you recommend EBUS as an initial approach or
would you go straight to mediastinoscopy where you can get lymph
node architecture?
DrAndrade.A lot of it depends on your pretest probability. The
main thing you want to avoid is missing a malignancy. If a patient
has a clinical picture suggestive of sarcoid, and EBUS-FNA cytol-
ogy demonstrates sarcoid that is noncaseating granuloma, I will
stop there. However, all of my patients provide consent for media-
stinoscopy, and I tell them if there’s any doubt, we will proceed
with a mediastinoscopy.
Dr Fernando. So your initial approach would still be EBUS for
those patients?
Dr Andrade. Yes.
Dr Fernando.Another question going on from that is, when you
have a patient who has a known diagnosis of cancer but who does
not have MLN enlargement by computed tomography or positron
emission tomography abnormalities, do you recommend EBUS
in those patients with clinically normal lymph nodes on the basisery c March 2010
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Sof their imaging or would you perform mediastinoscopy in those
patients?
Dr Andrade. I think that decision depends on the surgeon. In
my practice, a patient with a normal mediastinum and early-stage
cancer will undergo an EBUS. If I obtain good samples on
ROSE intraoperatively, I will then proceed with a lobectomy. How-
ever, I would not encourage surgeons who are not experienced with
EBUS to do this until they have passed their learning curve.
Dr Fernando. You still have a fairly significant NPV for media-
stinoscopy, so why perform the EBUS if you’re going to then per-
form a thoracoscopy? Are you going to then go on to perform
a mediastinoscopy after the EBUS?
Dr Andrade. There are 2 points here. One, are you going to
stage the mediastinum or not. That’s another point of discussion.
By assuming that one decides to stage the mediastinum, and on
the basis of our experience with nearly 200 EBUS procedures, I
can now confidently say that if the clinical stage is I and the
ROSE demonstrates a good sample with benign lymphocytes, I
do not confirm it with mediastinoscopy. However, if I have any
shred of doubt, I will do a mediastinoscopy.
Dr Thomas D’Amico (Durham, NC). That was a good study,
well designed and well performed. I have 2 questions. Did you
say if you had any complications from your 200 EBUS-FNAs?
Were there any significant complications?
Dr Andrade. No, I didn’t say. If you look at all of them, we had
3 patients out of almost 200 who stayed overnight for respiratory
decompensation. That has been the only complication we have
had so far.
Dr D’Amico. I think the 2 most important findings, other than
how well your NPV is, are that you have twice as many lymph
nodes per station, as in much of the literature, for which you are
to be congratulated, and that you trust ROSE, which a lot of other
practitioners have given up on. How have you perfected ROSE to
the point that you can trust it to do a secondary procedure?
Dr Andrade. We are fortunate to have outstanding pathologists
at our institution. I think that is the only reason we can get away
with that. They have extensive experience with transbronchial nee-
dle aspiration biopsy. A cytologist has to have specific experience
in this to be able to interpret these samples reliably.
Dr F. Detterbeck (New Haven, CT). First, I think it’s more im-
portant to calculate things by patient and not by node. You artifi-The Journal of Thoracic and Cacially make your numbers look better when you calculate it by
node, and I think you really have to do it by patient. Second, I think
you really can’t make a statement about the usefulness of this for
staging lung cancer when you’re also mixing in people and just try-
ing to get a diagnosis of mediastinal tissue, such as for sarcoid. I
think you have to separate that. Third, this is an important contribu-
tion. I think it is an important fact that you have done this carefully.
It makes a difference whether somebody is invested in a technique
and does it well. You have sampled a lot of nodes and you have
been careful to look at your results, and I can tell you that I think
EBUS looks good in some literature reports, but in some places
where it’s done, where people stick 1 node and then get out and
don’t do a good job, they are not going to get nearly as good results.
Thoracic surgeons who have a vested interest in appropriately stag-
ing the mediastinum are more likely to do a good job, such as you
have done.
Dr Andrade. Thank you.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). In that one
case with an FP, is it your practice to change your needle for
each lymph node station? Also, did you look in retrospect at
what the cause was of that FP reading? Were the cytopatholo-
gists reading the contamination of cells from the airway on the
way in?
Dr Andrade. The first answer is yes, we do change our needle.
If we first diagnose a malignant lymph node, we do not use that
needle again. In response to the FP case, this particular patient
had a distal left main stem squamous cell cancer. I purposefully
biopsied the subcarinal lymph nodes through the right main stem
bronchus to avoid any potential contamination. Eventually, he
underwent surgery and required a carinal pneumonectomy because
there was a carcinoma in situ extending all the way across the
carina into the proximal right main stem. What I do now if I have
any suspicion of contaminations is to biopsy level 7 via EUS or
mediastinoscopy.
Dr Nasser Altorki (New York, NY). Rafael, I have a quick ques-
tion for you. Do you have any experience with diagnosis of N1 sta-
tions?
Dr Andrade. Yes. We didn’t mention it here. We do sample N1
lymph nodes. We don’t do it as a staging procedure. We do it more
in patients with a diagnosis of probable lung cancer and we’re sam-
pling to get a tissue diagnosis.rdiovascular Surgery c Volume 139, Number 3 583
